[Form 4] Bio-Techne Corp. Insider Trading Activity

Rhea-AI Filing Summary

Shane Bohnen, SVP – General Counsel of Bio-Techne Corp (TECH), reported multiple option exercises, restricted stock unit vesting events and a small sale on 08/15/2025. The Form 4 shows a non-derivative acquisition of 1,718 shares (transaction code M) at $0 and a sale of 527 shares at $53.60, leaving 4,385 shares beneficially owned after the sale. The filing details many derivative holdings: several stock options exercisable at strike prices from $47.60 to $120.46, totaling tens of thousands of underlying shares, plus multiple restricted stock unit and performance award pools. Notable items include exercises or acquisitions that increased holdings by large blocks of shares via option-related transactions and performance awards that vest on future dates if goals are met.

Insights

Financial Analyst

TL;DR: Insider executed option-related transactions increasing equity exposure while also selling a small block of shares.

The report indicates active equity compensation activity for a senior executive: acquisitions (including option-related acquisitions coded M and multiple award grants/vests) materially increase the executive's potential equity stake through tens of thousands of underlying shares. The 527-share disposition at $53.60 is modest relative to overall derivative holdings. The schedule of strikes and vesting dates shows a multi-year compensation runway, which can dilute or align incentives depending on future vesting and exercise behavior.

Corporate Governance Expert

TL;DR: Filing documents routine executive compensation events and a minor open-market sale; no governance red flags disclosed.

Transactions appear to be standard equity compensation exercises, vesting, and performance-based awards for a named officer who is also a director. The presence of performance-conditioned awards and staggered vesting schedules is consistent with typical retention and performance alignment practices. The document does not disclose any related-party unusual arrangements or departures from standard grant terms.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bohnen Shane

(Last) (First) (Middle)

614 MCKINLEY PLACE NE

(Street)

MINNEAPOLIS MN 55413

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [ TECH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP - General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
08/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/15/2025		M		1,718	A	$0	4,912	D
Common Stock	08/15/2025		F		527	D	$53.6	4,385	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$47.6							(1)	08/07/2026	Common Stock	8,848		8,848	D
Stock Option (Right to Buy)	$66.97							(1)	08/05/2027	Common Stock	8,944		8,944	D
Stock Option (Right to Buy)	$120.46							(1)	08/06/2028	Common Stock	3,460		3,460	D
Stock Option (Right to Buy)	$94.52							(2)	08/15/2029	Common Stock	3,508		3,508	D
Stock Option (Right to Buy)	$73.76							(3)	04/03/2030	Common Stock	3,928		3,928	D
Restricted Stock Units	(4)							(5)	(5)	Common Stock	2,259		2,259	D
Stock Option (Right to Buy)	$84.61							(6)	08/15/2030	Common Stock	16,302		16,302	D
Restricted Stock Units	(4)	08/15/2025		M			50	(7)	(7)	Common Stock	50	$0	49	D
Performance Restricted Stock Units	(4)							(8)	(8)	Common Stock	4,802		4,802	D
Performance Stock Option (Right to Buy)	$84.61							(8)	(8)	Common Stock	12,924		12,924	D
Performance Restricted Stock Units	(4)							(9)	(9)	Common Stock	10,012		10,012	D
Restricted Stock Units	(4)	08/15/2025		M			1,668	(10)	(10)	Common Stock	1,668	$0	3,338	D
Stock Option (Right to Buy)	$74.91							(11)	08/15/2034	Common Stock	13,488		13,488	D
Performance Restricted Stock Units	(4)	08/15/2025		A		13,992		(12)	(12)	Common Stock	13,992	$0	13,992	D
Restricted Stock Units	(4)	08/15/2025		A		6,996		(13)	(13)	Common Stock	6,996	$0	6,996	D
Stock Option (Right to Buy)	$53.6	08/15/2025		A		17,897		(14)	08/15/2035	Common Stock	17,897	$0	17,897	D

Explanation of Responses:

1. Fully exercisable.

2. Options to purchase 876 shares vest on each of 8/15/2023, 8/15/2025 and 8/15/2026, and options to purchase 880 shares vest on 8/15/2024.

3. Options to purchase 982 shares vest on each of 4/3/2024, 4/3/2025, 4/3/2026 and 4/3/2027.

4. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.

5. 2,259 restricted stock units vest on 4/3/2026.

6. Options to purchase 4,076 shares vest on 8/15/2024 and 8/15/2026, and options to purchase 4,075 shares vest on 8/15/2025 and 8/15/2027.

7. 49 restricted stock units vest on 8/15/2026.

8. Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

9. Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

10. 1,669 restricted stock units vest on each of 8/15/2026 and 8/15/2027.

11. Options to purchase 3,372 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028.

12. Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

13. 2,332 restricted stock units vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.

14. Options to purchase 5,966 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 5,965 shares vest on 8/15/2028.

	/s/ Shane Bohnen	08/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Shane Bohnen report on the Form 4 for TECH?

The Form 4 reports a non-derivative acquisition of 1,718 shares (code M), a sale of 527 shares at $53.60, and multiple derivative transactions including exercises, option holdings and restricted stock/unit awards.

How many shares does Shane Bohnen beneficially own after the reported transactions?

After the reported transactions the filing shows 4,385 shares beneficially owned (direct).

Are there performance-based awards disclosed for TECH insider activity?

Yes. The filing lists multiple performance restricted stock units and a performance stock option that vest in full or in part if certain goals are achieved, with specified future vesting/ certification dates.

What is the range of strike prices for the stock options held by Shane Bohnen?

The disclosed option strike prices range from $47.60 to $120.46 across multiple option awards.

Do the transactions indicate immediate cash proceeds to the reporting person?

The only cash sale shown is the 527-share disposition at $53.60; several acquisitions are listed at a price of $0, consistent with option exercises or awards being converted rather than open-market purchases.